一种新型X因子变异的特征,p.F139L,与异合体和复合异合体形式的出血有关
Marit Hellum1, Marit Sletten2, Marie S Le3
1Dept. of Medical Biochemistry, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Dept. of Medical Biochemistry, Oslo University Hospital HF, Oslo, Norway.
Thrombosis research
|August 5, 2025
概括
一种新的X因子 (FX) 变异,p.F139L,导致一种罕见的出血障碍. 这种基因突变导致I型FX缺陷,导致受影响个体的轻度至中度出血倾向.
科学领域:
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 遗传X因子 (FX) 缺乏症是一种罕见的出血障碍.
- 根据基因型,FX缺乏症可以从轻度到严重程度.
- 在患有FX缺乏症的患者中,出血并发症很常见.
研究的目的:
- 在两个无关联的个体中发现的新型外汇变异的特征.
- 调查新FX变种对凝血的功能影响.
- 了解外汇缺陷的结构和分子基础.
主要方法:
- 凝血测定包括PT快速和APTT.
- 测量外汇活动和外汇抗原水平.
- 血栓生成试验,DNA测序,in silico预测,结构分析和体外表达研究.
主要成果:
- 一种新的误解变异 (p.F139L) 在异合体和复合异合体形式中被确定.
- 患有p.F139L变异的个体表现出减少的FX活性和抗原水平 (I型缺乏症).
- 结构分析表明,p.F139L变体破坏了FX蛋白的稳定,影响了细胞内处理.
结论:
- 新的FX变种p.F139L导致I型FX缺乏症.
- 这种缺乏与轻度至中度出血倾向有关.
- 这种变异可能会影响FX蛋白结构和细胞内处理.
相关概念视频
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
X-linked Traits
55.3K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
55.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
909
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
909
Pleiotropy
41.1K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
41.1K
Coagulation
7.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.4K


